CALL US: 1-855-483-4325

Anti-CD3 (Teplizumab) for Prevention of Diabetes in Relatives At Risk for Type 1 Diabetes Mellitus

Purpose

The purpose of this research study is to see if giving an investigational drug called Teplizumab will delay or prevent type 1 diabetes. For more information about this study, contact Jessica Ferguson by phone, 352-294-5761, or email, jaycee@peds.ufl.edu

Keywords

diabetes, prevention, trialnet, anti-cd3, teplizamub

Principal Investigator

Desmond Schatz, M.D.

Department

PEDIATRICS

Contact Information

schatz@ufl.edu
(352) 334-1390

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams